The biotech started by Loxo founder Josh Bilenker and former Novartis executive Jeff Engelman has advanced three cancer drugs ...

CEO Vlad Coric said the company has a patient hub, payer managers and a small sales force set up to ensure a successful ...

The alliance, which could be worth more than $5 billion, is one of a handful of deals Novartis has struck with China-based ...

A licensing deal worth at least $200 million will give Novartis access to a preclinical RNA medicine designed to combat ...

Biopharmaceutical firms in the U.S. and Europe are turning to China’s biotech sector for new medicines, with licensing ...

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...

The asset deal thrusts AbbVie to the forefront of the psychedelic field, handing it a therapy that recently scored positive ...

Faster review times could leave drugmakers vulnerable to litigation, while new Trump administration priorities add more ...

An $885M deal with BeOne Medicine gives the pharma financier rights to a revenue stream from global sales of Imdelltra, which ...

Co-founded by RNA interference pioneer John Maraganore and former Medicines Company head Clive Meanwell, Corsera Health is ...

A federal register notice confirmed dates for the anticipated advisory meeting, which will follow an FDA decision to narrow COVID boosters' approval and comes as CDC leadership is in turmoil.

AMX0035 missed the goals of a study in progressive supranuclear palsy. Elsewhere, Novartis and BioArctic struck a deal, and Genentech started building its first East Coast factory.